Neuropsychiatric Systemic Lupus Erythematosus with Cerebral Vasculitis and Lupus Nephritis Successfully Treated with High-dose Glucocorticoids and Mycophenolate Mofetil.

Abstract

Neuropsychiatric systemic lupus erythematosus (NPSLE) with cerebral vasculitis is rare, and its prognosis is unfavorable. High-dose glucocorticoids and cyclophosphamide are widely used for the treatment of NPSLE, but cyclophosphamide has a risk of cervical intraepithelial neoplasia and ovarian insufficiency, which may discourage its use in young women. We experienced a case of NPSLE with cerebral vasculitis and lupus nephritis that responded successfully to glucocorticoids and mycophenolate mofetil (MMF). MMF might be a treatment option for NPSLE without concern for reproductive toxicity. However, there are only a few reports on the efficacy of MMF in NPSLE, and further investigations are needed.

• Authors: Saki Tanaka, Takeshi Kawaguchi, Risa Kudo, Masatoshi Kimura, Yuki Rikitake, Chihiro Iwao, Mao Rikitake, Kosho Iwao, Ayako Aizawa, Yumi Kariya, Motohiro Matsuda, Shunichi Miyauchi, Ichiro Takajo, Kunihiko Umekita
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 61 Issue 20 Pg. 3131-3135 (Oct 15 2022) ISSN: 1349-7235 [Electronic] Japan
• PMID: 35283391 (Publication Type: Case Reports, Journal Article)

Chemical References

• Glucocorticoids
• Immunosuppressive Agents
• Cyclophosphamide
• Mycophenolic Acid

Topics

• Cyclophosphamide (therapeutic use)
• Female
• Glucocorticoids (therapeutic use)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Lupus Erythematosus, Systemic (complications, drug therapy)
• Lupus Nephritis (complications, drug therapy)
• Lupus Vasculitis, Central Nervous System (complications, drug therapy)
• Mycophenolic Acid (therapeutic use)